logo

For the Inventor, By the Inventor

San Francisco, CA, United States of America

Kyle MacBeth

This inventor holds 14 USPTO granted patents and 8 published patent applications and 4 EPO patents, primarily in Cancer Treatment. Top assignees: Celgene Corporation, Agios Pharmaceuticals, Inc.. Active years: 2013-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kyle MacBeth. Retrieved from https://idiyas.com/inventor/kyle-macbeth

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 14 

% Patents Active = 78.6

 

Average Co-Inventor Count = 4.6

ph-index = 4

Forward Citations = 59(Granted Patents)


Company Filing History:

goldMedal14 out of 561 
 
Celgene Corporation
 patents
silverMedal2 out of 99 
 
Agios Pharmaceuticals, Inc.
 patents
where one patent can have more than one assignee

Years Active: 2013-2023

Loading Chart...
Loading Chart...
Areas of Expertise:
Hematologic Malignancy
Antiproliferative Compounds
Drug Efficacy
Combination Therapy
Non-Small Cell Lung Cancer
Cytidine Analogs
Myeloma
B-Cell Lymphoma
Cancer Cells
Drug Resistance
14 patents (USPTO):Explore Patents
1. 11590117 - Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide (2023-02-28),
2. 11241423 - Antiproliferative compounds and methods of use thereof (2022-02-08),
3. 10996215 - Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers (2021-05-04),
4. 10695352 - Combination therapy for treating malignancies (2020-06-30),
5. 10653710 - Combination therapy for treating malignancies (2020-05-19),
6. 10245258 - Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide (2019-04-02),
7. 9968596 - Antiproliferative compounds and methods of use thereof (2018-05-15),
8. 9808451 - Antiproliferative compounds and methods of use thereof (2017-11-07),
9. 9693987 - Methods for treating cancers using oral formulations of cytidine analogs (2017-07-04),
10. 9499514 - Antiproliferative compounds and methods of use thereof (2016-11-22),
11. 9125884 - Methods for treating cancers using oral formulations of cytidine analogs (2015-09-08),
12. 9101579 - Inhibition of drug resistant cancer cells (2015-08-11),
13. 8841277 - Methods for treating non-small cell lung cancer using 5-azacytidine (2014-09-23),
14. 8492361 - Methods for treating non-small cell lung cancer using 5-azacytidine (2013-07-23),

Title: The Innovative Contributions of Kyle MacBeth

Introduction

Kyle MacBeth is a prominent inventor based in San Francisco, CA, known for his significant contributions to the field of pharmaceuticals. With a total of 14 patents to his name, he has made remarkable strides in the treatment of hematologic malignancies and cancer.

Latest Patents

Among his latest patents is a method for treating hematologic malignancies using a compound known as 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide. This patent outlines methods for treating, preventing, managing, and ameliorating conditions such as leukemia or myelodysplastic syndrome. Another notable patent involves antiproliferative compounds aimed at treating cancer, including leukemia, through the administration of specific compounds, often in combination with other agents.

Career Highlights

Kyle has worked with notable companies in the pharmaceutical industry, including Celgene Corporation and Agios Pharmaceuticals, Inc. His work has focused on developing innovative treatments that address critical health challenges.

Collaborations

Throughout his career, Kyle has collaborated with esteemed colleagues, including Antonia Lopez-Girona and Michael Pourdehnad, contributing to the advancement of cancer treatment methodologies.

Conclusion

Kyle MacBeth's innovative work and numerous patents reflect his dedication to improving cancer treatment and patient outcomes. His contributions continue to influence the pharmaceutical landscape significantly.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…